Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Operating Expenses for 3 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 38.19% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136.3 million through Dec 2025, down 58.89% year-over-year, with the annual reading at $136.3 million for FY2025, 58.89% down from the prior year.
  • Operating Expenses for Q4 2025 was $30.9 million at Inhibrx Biosciences, down from $33.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $161.0 million in Q2 2024, with the low at $28.7 million in Q2 2025.
  • Average Operating Expenses over 3 years is $58.7 million, with a median of $45.9 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 289.18% in 2024, then plummeted 82.18% in 2025.
  • Over 3 years, Operating Expenses stood at $89.9 million in 2023, then tumbled by 44.37% to $50.0 million in 2024, then plummeted by 38.19% to $30.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $30.9 million, $33.8 million, and $28.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.